Lactobacillus reuteri (Gastrus®) was not anymore available in the region

This study investigates the efficacy of a b.i.d. quadruple therapy containing Pylera® or L. reuteri for H. pylori infection.

Bismuth, metronidazole and tetracycline yielded high cure rates for H. pylori infection. Earlier studies suggested that the bismuth quadruple therapy may be effective when given twice-a-day rather than q.i.d. and that b.i.d. therapy was associated with fewer side effects. The addition of the probiotic Lactobacillus reuteri (Gastrus®) to Lactobacillus reuteri (Gastrus®) that has been shown to increase the cure rates by 10-14%. In another study bismuth supplementation with L. reuteri DSM 17938, in a modified low dose quadruple therapy provided good eradication rates (93.3%; 95% CI : 85-99%) in clinical practice.

Inclusion Criteria:

- Positive for H. pylori infection

Exclusion Criteria:

• Presence of malignancy
• Pregnancy or lactation
• Clinically significant diseases
• History of drug or alcohol abuse
• Allergy to pantoprazole or to any component of regimens used in the study
• Use of anti-secretory drugs, antibiotics or probiotics 4 weeks preceding the enrollment.